Casey N. Pinto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Casey N. Pinto has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Edward G. Dudley
Department of Food Science, The Pennsylvania State University
3 shared publications - Nkuchia M. M'IKanatha
Pennsylvania Department of Health
3 shared publications Anthony Possanza
Pharmacist, Geisinger Health System
2 shared publicationsKathryn Palisoc
Division of Hospital Medicine, Department of Medicine, University of Pittsburgh Medical Center - Memorial, York, Pennsylvania
2 shared publications- Kathryn Risher
Department of Public Health Sciences, Penn State University College of Medicine, Hershey, PA, USA
2 shared publications - Kelly Karpa
Quillen College of Medicine, East Tennessee State University Johnson City Tennessee USA
2 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Elsevier in American Journal of Preventive Medicine
Disparities and Temporal Trends in Syphilis Testing Among Pregnancies Ending in Stillbirth and Miscarriage, U.S., 2016–2023
- 30 October 2026
- Published by Elsevier in American Journal of Preventive Medicine
Open AccessDisparities and Temporal Trends in Syphilis Testing Among Pregnancies Ending in Stillbirth and Miscarriage, U.S., 2016–2023
- Open Access
- 19 May 2026
- Published by Elsevier in Public Health in Practice
- Vol. 11
Training healthcare providers in adolescent alcohol and substance use screening through project ECHO in rural Pennsylvania: A brief case report
- 19 May 2026
- Published by Elsevier in Public Health in Practice
- Vol. 11
Open AccessTraining healthcare providers in adolescent alcohol and substance use screening through project ECHO in rural Pennsylvania: A brief case report
- Open Access
- 5 December 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (49) , eadz5639
Distinguishing active HIV-1 infection from vaccine-induced seropositivity in HIV vaccine trial participants
Vaccine-induced seropositivity (VISP) causes antibodies produced by HIV-1 vaccines to react with standard serological tests, complicating diagnosis and leading to false positives. To distinguish VISP from true HIV infections, we developed a rapid, multiplexed companion electrochemical assay that integrates a three-dimensional–printed device with screen-printed electrodes coated with antigen, antibody, and methylene blue–labeled antisense oligonucleotide probes. The test delivers quantitative results within 5 minutes with calculated analytical limits of detection of 5.88 picograms per milliliter for p24 antigen, 10.96 picograms per milliliter for anti-p24 antibody, and 1259 copies per milliliter for HIV-1 RNA, with minimal cross-reactivity. Clinical testing with 104 plasma samples obtained from vaccinated/unvaccinated, HIV-positive/negative individuals demonstrated 95% sensitivity and 98% specificity in distinguishing active HIV-1 infection from VISP cases. Receiver operating characteristic analysis produced area under the curve values of 0.9888 for HIV-1 RNA, 0.9705 for anti-p24 antibody, and 0.9356 for p24 antigen. These findings highlight the potential to reduce false-positive results caused by VISP by integrating this diagnostic test in clinical trials and large-scale vaccination programs.
- 5 December 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (49) , eadz5639
Open AccessDistinguishing active HIV-1 infection from vaccine-induced seropositivity in HIV vaccine trial participants
Vaccine-induced seropositivity (VISP) causes antibodies produced by HIV-1 vaccines to react with standard serological tests, complicating diagnosis and leading to false positives. To distinguish VISP from true HIV infections, we developed a rapid, multiplexed companion electrochemical assay that integrates a three-dimensional–printed device with screen-printed electrodes coated with antigen, antibody, and methylene blue–labeled antisense oligonucleotide probes. The test delivers quantitative results within 5 minutes with calculated analytical limits of detection of 5.88 picograms per milliliter for p24 antigen, 10.96 picograms per milliliter for anti-p24 antibody, and 1259 copies per milliliter for HIV-1 RNA, with minimal cross-reactivity. Clinical testing with 104 plasma samples obtained from vaccinated/unvaccinated, HIV-positive/negative individuals demonstrated 95% sensitivity and 98% specificity in distinguishing active HIV-1 infection from VISP cases. Receiver operating characteristic analysis produced area under the curve values of 0.9888 for HIV-1 RNA, 0.9705 for anti-p24 antibody, and 0.9356 for p24 antigen. These findings highlight the potential to reduce false-positive results caused by VISP by integrating this diagnostic test in clinical trials and large-scale vaccination programs.
- 1 May 2025
- Published by American Public Health Association in American Journal of Public Health
- Vol. 115 (5) , 631-633
COVID-19 Policies and the Impact on STIs: Context, Equity, and Innovation
- 1 May 2025
- Published by American Public Health Association in American Journal of Public Health
- Vol. 115 (5) , 631-633
COVID-19 Policies and the Impact on STIs: Context, Equity, and Innovation
- Open Access
ViraLite: An Ultracompact HIV Viral Load Self-Testing System with Internal Quality Control
The availability of effective antiretroviral therapy has made HIV manageable, provided patients have consistent access to routine viral load (VL) testing. Nonetheless, access to frequent VL testing remains limited. There is a need for accessible, user-friendly testing systems that allow people living with HIV (PLHIV) to monitor their VL more frequently and empower self-management. Here, we developed ViraLite, a sample-to-answer, compact, accessible, and battery-powered system for HIV viral load monitoring. The system is built upon a probe-based RT-LAMP assay that allows for multiplexed detection and quantification. An internal quality control targeting the RNase P was incorporated to enhance the reliability of the results. A software-reconfigurable real-time sensing system empowered by machine learning and a smartphone-guided protocol was developed in tandem to analyze the multiplexed assay. We analyzed 45 clinically archived samples using ViraLite and benchmarked our results against qRT-PCR, which showed 21 positive and 23 negative samples. Using our process control, ViraLite first identified 17 inconclusive samples that would otherwise be classified as negative. Then, ViraLite classified 14 out of 15 HIV-positive samples (93.3%) and 13 out of 13 HIV-negative samples (100%). The incorporation of RNase P as a process control increased the sensitivity of ViraLite from 66.66% to 93.33%, while maintaining a high specificity (100%). To assess the acceptance of ViraLite among PLHIV, we recruited 480 participants from online and three clinical sites to complete a survey. Over 86% of participants indicated ViraLite had benefits in convenience and privacy, on the other hand 61% of participants indicated concerns with test accuracy. The integration of compact hardware, a reliable assay, and smartphone guidance provides an accurate, easy to use system for PLHIV to self-manage their viral load and update their prescriptions frequently.
Open AccessViraLite: An Ultracompact HIV Viral Load Self-Testing System with Internal Quality Control
The availability of effective antiretroviral therapy has made HIV manageable, provided patients have consistent access to routine viral load (VL) testing. Nonetheless, access to frequent VL testing remains limited. There is a need for accessible, user-friendly testing systems that allow people living with HIV (PLHIV) to monitor their VL more frequently and empower self-management. Here, we developed ViraLite, a sample-to-answer, compact, accessible, and battery-powered system for HIV viral load monitoring. The system is built upon a probe-based RT-LAMP assay that allows for multiplexed detection and quantification. An internal quality control targeting the RNase P was incorporated to enhance the reliability of the results. A software-reconfigurable real-time sensing system empowered by machine learning and a smartphone-guided protocol was developed in tandem to analyze the multiplexed assay. We analyzed 45 clinically archived samples using ViraLite and benchmarked our results against qRT-PCR, which showed 21 positive and 23 negative samples. Using our process control, ViraLite first identified 17 inconclusive samples that would otherwise be classified as negative. Then, ViraLite classified 14 out of 15 HIV-positive samples (93.3%) and 13 out of 13 HIV-negative samples (100%). The incorporation of RNase P as a process control increased the sensitivity of ViraLite from 66.66% to 93.33%, while maintaining a high specificity (100%). To assess the acceptance of ViraLite among PLHIV, we recruited 480 participants from online and three clinical sites to complete a survey. Over 86% of participants indicated ViraLite had benefits in convenience and privacy, on the other hand 61% of participants indicated concerns with test accuracy. The integration of compact hardware, a reliable assay, and smartphone guidance provides an accurate, easy to use system for PLHIV to self-manage their viral load and update their prescriptions frequently.
- Open Access
- 29 March 2025
- Published by SAGE Publications in Digital Health
- Vol. 11
Use of telehealth by US adults with depression or anxiety disorder: Results from 2022 Health Information National Trends Survey
Background: Telehealth use has significantly increased recently. However, little is known about its use by individuals with depression or anxiety disorders. This study aims to explore the patterns of telehealth use among those individuals. Methods: Data used were from the 2022 Health Information National Trends Survey (HINTS) cycle 6. Weighted logistic regression was performed to test the association between depression/anxiety disorder and telehealth use, and to explore reasons for using/not using telehealth among those with depression/anxiety, compared to those without. Results: Out of the 4952 study participants, 2887 (weighted percentage: 39.36%) had used telehealth in the past 12 months. Those with depression/anxiety disorder had significantly higher telehealth use, compared to those without (57% vs. 32%; OR = 2.65; 95% CI: (2.04, 3.43)). Factors affecting telehealth use could differ by depression/anxiety disorder status. Among those with depression/anxiety disorder, being woman or married was not associated with telehealth use, whereas they were significant factors among those without depression/anxiety disorder. Among those with depression/anxiety, non-Hispanic Black participants (OR = 0.51; CI: (0.78, 0.94)) were less likely to use telehealth, compared to non-Hispanic White participants; additionally, higher income was associated with telehealth use. Regarding reasons for using telehealth, convenience (OR = 1.80; CI: (1.21, 2.68)) and avoiding COVID infection (OR = 1.40; CI: (1.06, 1.86)) were more likely considered by those with depression/anxiety disorder. Conclusion: Individuals with depression/anxiety disorder were more likely to use telehealth and to do so for reasons of convenience and avoiding infection. Promoting telehealth to those with depression/anxiety disorder should consider their unique utilization patterns.
- 29 March 2025
- Published by SAGE Publications in Digital Health
- Vol. 11
Open AccessUse of telehealth by US adults with depression or anxiety disorder: Results from 2022 Health Information National Trends Survey
Background: Telehealth use has significantly increased recently. However, little is known about its use by individuals with depression or anxiety disorders. This study aims to explore the patterns of telehealth use among those individuals. Methods: Data used were from the 2022 Health Information National Trends Survey (HINTS) cycle 6. Weighted logistic regression was performed to test the association between depression/anxiety disorder and telehealth use, and to explore reasons for using/not using telehealth among those with depression/anxiety, compared to those without. Results: Out of the 4952 study participants, 2887 (weighted percentage: 39.36%) had used telehealth in the past 12 months. Those with depression/anxiety disorder had significantly higher telehealth use, compared to those without (57% vs. 32%; OR = 2.65; 95% CI: (2.04, 3.43)). Factors affecting telehealth use could differ by depression/anxiety disorder status. Among those with depression/anxiety disorder, being woman or married was not associated with telehealth use, whereas they were significant factors among those without depression/anxiety disorder. Among those with depression/anxiety, non-Hispanic Black participants (OR = 0.51; CI: (0.78, 0.94)) were less likely to use telehealth, compared to non-Hispanic White participants; additionally, higher income was associated with telehealth use. Regarding reasons for using telehealth, convenience (OR = 1.80; CI: (1.21, 2.68)) and avoiding COVID infection (OR = 1.40; CI: (1.06, 1.86)) were more likely considered by those with depression/anxiety disorder. Conclusion: Individuals with depression/anxiety disorder were more likely to use telehealth and to do so for reasons of convenience and avoiding infection. Promoting telehealth to those with depression/anxiety disorder should consider their unique utilization patterns.
- 31 October 2024
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 52 (4) , 211-216
Congenital Syphilis in the US: A Narrative Review
Congenital syphilis (CS) continues to pose a significant global challenge. There has been a marked increase in reported cases in the United States, with 102.5 cases per 100,000 live births in 2022 compared with 11.6 cases per 100,000 live births in 2014. Congenital syphilis can lead to a range of severe complications, including premature birth, intrauterine growth restriction, miscarriage, perinatal death, stillbirth, and postnatal complications that may persist into later life. Maternal/parental factors such as age, race/ethnicity, occupation, income level, access to health care services, and incarceration have been linked to higher rates of CS. In addition, pregnant individuals who engage in high-risk behaviors such as sex work, having multiple sexual partners, or substance use are at a higher risk of exposure and subsequent infection. Routine screening for syphilis during pregnancy is crucial for its detection, timely management, and prevention of CS. The asymptomatic nature of the latent stage of syphilis further underscores the importance of prenatal syphilis screening. Studies in various countries have shown that early or first antenatal care visit screening for CS is cost-effective. This review article critically evaluates the current knowledge of CS in the United States, including its prevalence, social determinants of health, prevention efforts, challenges, the significance of screening, and the call to action to address the rising trend. (See Graphical Abstract)
- 31 October 2024
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 52 (4) , 211-216
Congenital Syphilis in the US: A Narrative Review
Congenital syphilis (CS) continues to pose a significant global challenge. There has been a marked increase in reported cases in the United States, with 102.5 cases per 100,000 live births in 2022 compared with 11.6 cases per 100,000 live births in 2014. Congenital syphilis can lead to a range of severe complications, including premature birth, intrauterine growth restriction, miscarriage, perinatal death, stillbirth, and postnatal complications that may persist into later life. Maternal/parental factors such as age, race/ethnicity, occupation, income level, access to health care services, and incarceration have been linked to higher rates of CS. In addition, pregnant individuals who engage in high-risk behaviors such as sex work, having multiple sexual partners, or substance use are at a higher risk of exposure and subsequent infection. Routine screening for syphilis during pregnancy is crucial for its detection, timely management, and prevention of CS. The asymptomatic nature of the latent stage of syphilis further underscores the importance of prenatal syphilis screening. Studies in various countries have shown that early or first antenatal care visit screening for CS is cost-effective. This review article critically evaluates the current knowledge of CS in the United States, including its prevalence, social determinants of health, prevention efforts, challenges, the significance of screening, and the call to action to address the rising trend. (See Graphical Abstract)
- 1 September 2024
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 51 (9) , 630
Finding a Home as a Nurse Practitioner in the STI Field
- 1 September 2024
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 51 (9) , 630
Finding a Home as a Nurse Practitioner in the STI Field
- Open Access
Association between self-reported STI symptoms and stillbirth in sub-Saharan Africa using nationally representative household surveys
Stillbirths are a known outcome of untreated sexually transmitted infections (STIs). Sub-Saharan Africa (SSA) shares a disproportionate burden of both stillbirths (2015: 29/1000 births vs 3/1000 births in high income countries globally) and STIs. Nationally representative survey data can inform stillbirth prevention measures in multiple countries in the SSA region, with greater generalizability than clinic-based studies. We assessed the association between any self-reported STI symptoms (STI diagnosis, abnormal genital discharge, genital sore or ulcer) in the last 12 months and stillbirth in the prior five years, among women aged 15-49 years participating in nationally representative Demographic and Health Surveys (DHS) in 19 countries in SSA between 2015-2021 and reporting a pregnancy in the five years prior to interview. We used multivariable logistic regression models adjusting for maternal age, wealth index, education level of mother, cigarette smoking behaviors, health care utilization and country of residence. Among 160,995 SSA women who reported being pregnant at least once between 2011-2021, 18.0% (25,596) reported any STI symptom in the prior year and 1.9% (3,205) reported a stillbirth in the past five years. Women who self-reported STI symptoms in the past year had 1.30 (95% CI 1.16-1.47) times the odds of stillbirth in the prior five years compared to women who did not report STI symptoms. Women 35-49 years old had 1.17 (95% CI 1.04-1.33) times the odds of stillbirth compared to those 15-24 years old. The association found between self-reported STI symptoms and stillbirth highlights the need for increased screening for STI symptoms and subsequent treatment among pregnant women in SSA.
Open AccessAssociation between self-reported STI symptoms and stillbirth in sub-Saharan Africa using nationally representative household surveys
Stillbirths are a known outcome of untreated sexually transmitted infections (STIs). Sub-Saharan Africa (SSA) shares a disproportionate burden of both stillbirths (2015: 29/1000 births vs 3/1000 births in high income countries globally) and STIs. Nationally representative survey data can inform stillbirth prevention measures in multiple countries in the SSA region, with greater generalizability than clinic-based studies. We assessed the association between any self-reported STI symptoms (STI diagnosis, abnormal genital discharge, genital sore or ulcer) in the last 12 months and stillbirth in the prior five years, among women aged 15-49 years participating in nationally representative Demographic and Health Surveys (DHS) in 19 countries in SSA between 2015-2021 and reporting a pregnancy in the five years prior to interview. We used multivariable logistic regression models adjusting for maternal age, wealth index, education level of mother, cigarette smoking behaviors, health care utilization and country of residence. Among 160,995 SSA women who reported being pregnant at least once between 2011-2021, 18.0% (25,596) reported any STI symptom in the prior year and 1.9% (3,205) reported a stillbirth in the past five years. Women who self-reported STI symptoms in the past year had 1.30 (95% CI 1.16-1.47) times the odds of stillbirth in the prior five years compared to women who did not report STI symptoms. Women 35-49 years old had 1.17 (95% CI 1.04-1.33) times the odds of stillbirth compared to those 15-24 years old. The association found between self-reported STI symptoms and stillbirth highlights the need for increased screening for STI symptoms and subsequent treatment among pregnant women in SSA.
- Open Access
- 20 July 2022
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 30, 487-488
Increase in quinolone resistance among salmonella isolates from retail meat samples is driven by Salmonella enteritidis and Salmonella infantis
- 20 July 2022
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 30, 487-488
Open AccessIncrease in quinolone resistance among salmonella isolates from retail meat samples is driven by Salmonella enteritidis and Salmonella infantis